Omni Health Inc (OMHE)

[goodibag]

OMHE has an advanced Biotech R&D lab and scientists have developed cannabinoid-based drug therapies / medicines. Clinical Trial Started



Click to Read News>>>OMHE had announced all this earlier this year

To successfully implement our plans, Omni Health has been accumulating clinical research, regulatory experience and technology. We've recruited professional talent and we are building critical infrastructure.

Click to Read News>>>OMHE owns a Medical MJ R&D Lab

MIAMI, FL--(Marketwired - May 4, 2017) - Omni Health, Inc., ( OTC PINK : OMHE ), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, announced today the grand opening of its state of the art biotech R&D and manufacturing laboratory facility in Miami, Florida.

Click to Read News>>>OMHE R&D Scientist: Dr. Arkady Uryash, MD, PhD


Click to Read News>>>OMHE R&D Scientist: Dr. Lawrence E. Samuels, MD

Dr. Uryash is the Director of Biomedical Research for the internship program of Mount Sinai Medical Center and Associate Professor of Cardiology and Vascular Biology for Mount Sinai Center in Miami. As an experienced Director of Research and Development, Dr. Uryash is knowledgeable in U.S. Food and Drug Administration (FDA) regulation, research and development, and clinical trials. Dr. Uryash has previously served as CEO of a biotech company and is experienced in the management of biotech company operations, interdisciplinary team recruitment, and intellectual property. He has published numerous articles in peer-review journals and is a recipient of several academic awards and honors.

Dr. Lawrence E. Samuels, the chief of dermatology at St. Luke's Hospital in St. Louis and a widely-respected leader in his medical field, founded RX Systems PF in 1966 and is highly knowledgeable in pH-balanced, Glypoic Complex-based products, retinols and moisturizers for the face and body, anti-aging, skin care and hair repair products. Dr. Samuels will provide access to a lucrative niche market of doctors' offices and medical facilities. Dr. Samuels is a member of the teaching faculty at Washington University Medical School and he has provided expert dermatological care for more than three decades. He's a board-certified dermatologist and a member of the American Academy of Dermatology and the American Society for Dermatologic Surgery.

Click to Read News>>>OMHE R&D Scientist: Dr. Karyemaitre Aliffe, MD

In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics -- evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.

The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.

Folks! OMHE will hit $1 soon.